|
業務類別
|
Biotechnology |
|
業務概覽
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
| 公司地址
| 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 362-6295 |
| 傳真號碼
| +1 858 362-6296 |
| 公司網頁
| https://www.anaptysbio.com |
| 員工數量
| 104 |
| Mr. Daniel R. Faga |
Director, President and Chief Executive Officer |
美元 685.45K |
20/04/2026 |
|
|
| Mr. Hollings C. Renton |
Independent Director |
03/03/2026 |
| Mr. Oleg Nodelman |
Independent Director |
03/03/2026 |
| Mr. John P. Schmid |
Independent Director |
03/03/2026 |
| Mr. Daniel R. Faga |
Director, President and Chief Executive Officer |
20/04/2026 |
| Mr. John A. Orwin, M.B.A. |
Chairman of the Board |
03/03/2026 |
| Ms. Susannah Gray, M.B.A. |
Director |
27/03/2026 |
|
|
|
|
